¼¼°èÀÇ Ã·´Ü Ä¡·áÁ¦(ATMP) °³¹ß Á¦Á¶ ¼öŹ ±â°ü(CDMO) ½ÃÀå º¸°í¼­(2025³â)
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025
»óǰÄÚµå : 1702692
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,496,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,390,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,284,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

÷´Ü Ä¡·áÁ¦(ATMP) °³¹ß Á¦Á¶ ¼öŹ ±â°ü(CDMO) ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â 115¾ï 3,000¸¸ ´Þ·¯·Î ¼ºÀåÇϸç CAGRÀº 16.7%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ¿¹Ãø±â°£ÀÇ ¼ºÀåÀº CDMOÀÇ °íÅõÀÚ, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á(CGT) ºÐ¾ßÀÇ ½ÅÈï ±â¾÷ Áõ°¡, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á °³¹ßÀ» À§ÇÑ º¸Á¶±Ý°ú ÅõÀÚ Áõ°¡, ÀǾàǰ ¿¬±¸°³¹ßºñ Áõ°¡, ATMPÀÇ ÀÓ»ó½ÃÇè¼ö Áõ°¡ µî¿¡ ±âÀÎÇÑ´Ù°í »ý°¢µË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â AAV ¹ÙÀÌ¿À Á¦Á¶ ½Ã¼³ÀÇ Áøº¸, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á Á¦Á¶ÀÇ È®´ë, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·áÀÇ ±â¼úÀû Áøº¸, °íµµÀÇ Ç÷§ÆûÀ̳ª ±â¼ú¿¡ÀÇ ¾×¼¼½º¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡Áü, CRISPRÀ̳ª Â÷¼¼´ë ½ÃÄö¼­ µîÀÇ °íµµÀÇ ±â¼úÀ» Æ÷ÇÔÇØ Á¤¹Ðµµ¸¦ ³ôÀÌ´Â µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

÷´Ü Ä¡·áÁ¦(ATMP) °³¹ß Á¦Á¶ ¼öŹ ±â°ü(CDMO)ÀÇ ¼ºÀåÀº ÀÓ»ó½ÃÇè Áõ°¡¿¡ ÀÇÇØ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÓ»ó½ÃÇèÀº ÀǾàǰ, Ä¡·á, ±â±â, ¿¹¹æÁ¶Ä¡ µî ÀÇ·á°³ÀÔÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» Æò°¡Çϱâ À§ÇØ Àΰ£À» ´ë»óÀ¸·Î ½Ç½ÃµÇ´Â Á¶»ç¿¬±¸À̸ç, Çõ½ÅÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ°í ¼¼°è Áúº´ ºÎ´ãÀÇ Áõ´ë¿¡ ÀÓÇϱâ À§ÇØ Áõ°¡ Ãß¼¼¿¡ ÀÖ½À´Ï´Ù. ÷´Ü Ä¡·á ÀǾàǰÀÇ »ç¿ëÀº Àü¹®ÀûÀÎ Àü¹® Áö½Ä°ú ÀÎÇÁ¶ó¸¦ Ȱ¿ëÇÏ´Â CDMO Á¦Á¶ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁý´Ï´Ù. ÀÓ»ó½ÃÇè µ¥ÀÌÅÍ´Â Á¦Á¶ °øÁ¤ ÃÖÀûÈ­, È®À强 È®º¸, ǰÁú À¯Áö¿¡ µµ¿òÀÌ µÇ¸ç, º¸´Ù Å« ÀÓ»óÀû/»ó¾÷Àû ¼ö¿ä¿¡ ºÎÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¿µ±¹À» °ÅÁ¡À¸·Î ÇÏ´Â ¾÷°è ´ÜüÀÎ ¿µ±¹ Á¦¾à°ø¾÷Çùȸ´Â 2023³â 11¿ù ¿µ±¹¿¡¼­ ½ÃÀÛµÈ ÀÓ»ó½ÃÇè ¾÷°è ÀüüÀÇ ¿¬°£ °Ç¼ö°¡ 4.3% ¹ÌÁõÇϰí 2021³â 394°Ç¿¡¼­ 2022³â 411°ÇÀ¸·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ¿Í °°ÀÌ, ÀÓ»ó½ÃÇè¼ö Áõ°¡°¡ ÷´Ü Ä¡·áÁ¦(ATMP) °³¹ß Á¦Á¶ ¼öŹ ±â°ü(CDMO)ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

÷´Ü Ä¡·áÁ¦(ATMP) °³¹ß Á¦Á¶ ¼öŹ ±â°ü(CDMO)ÀÇ ÁÖ¿ä ±â¾÷Àº ¼¼Æ÷ Ä¡·á Á¦Á¶ÀÇ ½É°¢ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏ°í ÆÄÆ®³Ê °³¹ß Ȱµ¿À» °¡¼ÓÈ­Çϱâ À§ÇØ Ã·´Ü ¼¼Æ÷ Ä¡·á Á¦Á¶ ¼­ºñ½ºÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶ ¼­ºñ½º´Â ÀüÀÓ»ó °³¹ßÀÇ Ãʱ⠴ܰèºÎÅÍ Èıâ ÀÓ»ó½ÃÇè, »ó¾÷È­±îÁöÀÇ ¼­ºñ½º¸¦ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù À̽º¶ó¿¤¿¡ º»»ç¸¦ µÐ ¼¼Æ÷ ¼Ö·ç¼Ç Àü¹® »ý¸í°øÇРȸ»çÀÎ Pluristem Therapeutics´Â ¼¼Æ÷ Ä¡·áÁ¦ Á¦Á¶ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ½Å±Ô »ç¾÷ºÎÀÎ PluriCDMO¸¦ ¼³¸³Çß½À´Ï´Ù. Ä¡·á¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¼¼Æ÷ À¯ÇüÀÇ Á¦Á¶¸¦ ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. PluriCDMO´Â ÀûÀýÇÑ Á¦Á¶ ±âÁØ(GMP)ÀÇ ¹üÀ§ ³»¿¡¼­ È®Àå °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ¹æ½ÄÀ¸·Î ¹èÄ¡ °£ÀÇ Àϰü¼ºÀ» º¸ÀåÇϸ鼭 °íǰÁúÀÇ ÀǾàǰÀ» ȯÀÚ¿¡°Ô Àü´ÞÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°, ±×¸®°í °æ±â ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã °æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

An advanced therapy medicinal product contract development and manufacturing organization (CDMO) is a specialized service provider that aids in the development and manufacturing of advanced therapy medicinal products. The objective of an advanced therapy medicinal product CDMO is to offer the expertise, infrastructure, and resources necessary for the development and production of these advanced therapies.

The main types of products handled by advanced therapy medicinal product CDMOs include gene therapy, cell therapy, and tissue-engineered products. Gene therapy involves the introduction, removal, or alteration of genetic material within a patient's cells to treat or prevent disease. This process can utilize viral or non-viral vectors to deliver therapeutic genes to target cells across various phases, such as phase I, phase II, phase III, and phase IV clinical trials. These therapies address a range of indications, including oncology, cardiology, central nervous system and musculoskeletal conditions, infectious diseases, dermatology, endocrine and metabolic disorders, genetic diseases, immunology and inflammation, ophthalmology, and hematology.

The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market research report is one of a series of new reports from The Business Research Company that provides advanced therapy medicinal products contract development and manufacturing organization (CDMO) market statistics, including the advanced therapy medicinal products contract development and manufacturing organization (CDMO) industry global market size, regional shares, competitors with advanced therapy medicinal products contract development and manufacturing organization (CDMO) market share, detailed advanced therapy medicinal products contract development and manufacturing organization (CDMO) market segments, market trends, and opportunities, and any further data you may need to thrive in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) industry. These advanced therapy medicinal products contract development and manufacturing organization (CDMO) market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market size has grown rapidly in recent years. It will grow from $5.31 billion in 2024 to $6.22 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be attributed to the increasing number of ATMP clinical trials, rising awareness and belief among researchers regarding the benefits of advanced therapy, the presence of several ATMP CDMOs, increasing efforts to develop novel therapies for various diseases, and supportive government initiatives.

The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market size is expected to see rapid growth in the next few years. It will grow to $11.53 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to the high investment of CDMOs, a growing number of emerging players in the cell and gene therapy (CGT) sector, increasing grants and investments for the development of cell and gene therapies, increasing pharmaceutical R&D spending, increasing number of clinical trials for ATMPs. Major trends in the forecast period include advancements in AAV biomanufacturing facilities, expansion of cell and gene therapy manufacturing, technological advancements in cell and gene therapy, increasing need for access to advanced platforms and technologies, and incorporating advanced technologies such as CRISPR and next-generation sequencing for heightened accuracy.

The growth of the advanced therapy medicinal products CDMO market is anticipated to be propelled by the increasing number of clinical trials. Clinical trials, which are research studies conducted in humans to assess the safety and efficacy of medical interventions such as drugs, treatments, devices, or preventive measures, are on the rise to meet the growing demand for innovative treatments and to tackle the increasing global disease burden. The utilization of advanced therapy medicinal products leads to a heightened demand for CDMO manufacturing services, which leverage specialized expertise and infrastructure. Clinical trial data assists in optimizing manufacturing processes, ensuring scalability, and maintaining quality to meet larger clinical and commercial demands. For example, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported a marginal increase of 4.3% in the overall number of industry clinical trials initiated in the UK per year, rising from 394 in 2021 to 411 in 2022. Thus, the escalating number of clinical trials is propelling the growth of the advanced therapy medicinal products CDMO market.

Major players in the advanced therapy medicinal products CDMO market are focusing on developing advanced cell therapy manufacturing services to address critical issues in cell therapy manufacturing and accelerate the development activities of their partners. These cell therapy manufacturing services, offered by contract development and manufacturing organizations, encompass services ranging from early preclinical development to late-stage clinical trials and commercialization. For instance, in January 2024, Pluristem Therapeutics Inc., an Israel-based biotech company specializing in cell solutions, introduced PluriCDMO, a new business division offering cell therapy manufacturing services. PluriCDMO utilizes a patented bioreactor system enabling 3D cell multiplication, facilitating the production of various cell types such as stem cells, induced pluripotent stem cells, exosomes, and immune therapies. PluriCDMO aims to deliver high-quality medicines to patients while ensuring batch-to-batch consistency in a scalable and cost-effective manner within good manufacturing practice settings.

In February 2022, Recipharm AB, a Sweden-based contract development and manufacturing organization (CDMO), acquired Vibalogics for an undisclosed sum. This acquisition is intended to bolster Recipharm's presence in advanced therapy medicinal products and enable expansion into additional biologic modalities such as viral vectors. The acquisition will allow Recipharm to broaden its technologies and modalities, positioning it to better serve the growing demand for specialist CDMO capabilities in viral manufacturing within the rapidly expanding biopharmaceutical industry. Vibalogics is a Germany-based virotherapy CDMO specializing in manufacturing oncolytic viruses, viral vaccines, and gene therapies.

Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market are Thermo Fisher Scientific Inc., Merck KGaA, Resonac Corporation, Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Recipharm AB, KBI Biopharma, Takara Bio Inc., Rentschler Biopharma SE, Ajinomoto Co. Inc., ElevateBio LLC, Fujifilm Diosynth Biotechnologies, Axplora Group GmbH, WuXi Advanced Therapies Inc., Celonic Group, Batavia Biosciences B.V., BioCentriq, Cytovance Biologics, Andelyn Biosciences, Genezen, AGC Biologics, ABL Manufacturing, Minaris Regenerative Medicine, Porton Advanced Solutions

North America was the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The advanced therapy medicinal product contract development and manufacturing organization (CDMO) market includes revenues earned by entities by providing services such as process development, analytical method development, good manufacturing practice manufacturing, and quality control testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced therapy medicinal products CDMO market also includes sales of bioreactors and fermenters, cryopreservation equipment, and laboratory instruments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on advanced therapy medicinal products contract development and manufacturing organization (cdmo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for advanced therapy medicinal products contract development and manufacturing organization (cdmo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Characteristics

3. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Trends And Strategies

4. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Growth Analysis And Strategic Analysis Framework

6. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Segmentation

7. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Regional And Country Analysis

8. Asia-Pacific Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

9. China Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

10. India Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

11. Japan Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

12. Australia Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

13. Indonesia Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

14. South Korea Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

15. Western Europe Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

16. UK Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

17. Germany Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

18. France Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

19. Italy Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

20. Spain Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

21. Eastern Europe Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

22. Russia Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

23. North America Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

24. USA Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

25. Canada Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

26. South America Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

27. Brazil Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

28. Middle East Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

29. Africa Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

30. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Competitive Landscape And Company Profiles

31. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Other Major And Innovative Companies

32. Global Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

34. Recent Developments In The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market

35. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â